Unmet need in CSU: Treatment guidelines

International guidelines** for the management of CSU1

Xolair® is the only licensed treatment option for CSU patients inadequately controlled with H1-antihistamines.1

Guidelines recommend adding on another therapy at third line instead of prescribing a different H1-antihistamine.

International guidelines for the management of CSU

*Patient verbatim and profile comes from hypothetical patient for illustrative purpose only

**Guidelines developed by European Academy of Allergy and Clinical Immunology, Global Allergy and Asthma European Network, European Dermatology Forum and the World Allergy Organization.

***Xolair® is also available as a lyophilized formulation

Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients

Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo.

References: 1. Zerbier T et al. Eur J Allergy Clin Immunol 2014;69:868–887. 2. Xolair® Summary of Product of Characteristics 2016. 3. Maurer M, et al. N Engl J Med 2013;368:924-935.

NP4 code: GLDEIM/IGE025E/0181

Terms of use - Privacy policy - About cookies - Cookie Settings - This site is intended for a global audience.

© 2017 Novartis Pharma